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Purpose: Glucocorticoids are used to prevent chronic lung allograft dysfunction 
(CLAD) after lung transplantation (LT). Our study was aimed at assessing the 
association between the glucocorticoid-induced transcript 1 gene (GLCCI1) variant, 
which modulates glucocorticoid sensitivity, and the postoperative lung function and 
development of CLAD after LT.  
Methods: A total of 71 recipients of LT were genotyped for the GLCCI1 variant 
(rs37972) and divided into 3 groups: the homozygous mutant allele (TT) group, the 
heterozygous mutant allele (CT) group, and the wild-type allele (CC) group. The 
results of pulmonary function tests were compared with the postoperative baseline 
values.  
Results: The total lung capacity (TLC) in the TT group was significantly lower than 
that in the CC group at 3 years after LT (P = 0.029). In the recipients of cadaveric LT, 
the TLC and forced expiratory volume in 1 second in the TT group were significantly 
lower than those in the CC groups, resulting in a significant worse CLAD-free survival 
at 3 years after LT (P = 0.016).  
Conclusion: The GLCCI1 variant was associated with a significant decrease of the 
TLC at 3 years after LT and the development of CLAD at 3 years, especially in patients 
undergoing cadaveric LT.  
Keywords: Lung transplantation; Glucocorticoid; Single nucleotide polymorphism; 
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The long-term survival after lung transplantation (LT) remains worse than that after 
other solid organ transplantations [1-3], and chronic lung allograft dysfunction (CLAD) 
is a major obstacle to the long-term survival after LT. To prevent CLAD after LT, 
adequate immunosuppression is key [4, 5]. At present, the most commonly used 
maintenance immunosuppression regimen after LT is a triple regimen consisting of a 
calcineurin inhibitor, mycophenolate mofetil and a glucocorticoid [3]. Of these, the 
doses of the calcineurin inhibitor and mycophenolate mofetil are currently adjusted by 
monitoring the trough blood levels of the drug in each patient, whereas the dose of the 
glucocorticoid is uniformly tapered to 5 to 10 mg per day for maintenance therapy, 
according to the body weight or body surface area of the patients. Because individual 
glucocorticoid sensitivity is known to be influenced by various factors [6-11], monitoring 
the therapeutic levels of glucocorticoids is not a realistic option. Nonetheless, 
recipients of LT generally require glucocorticoids over their lifetimes, although the 
successful withdrawal of glucocorticoids after LT has previously been reported in a few 
patients after LT [12, 13]. Given the difficulty in monitoring the therapeutic levels of 
glucocorticoids, the routinely used maintenance dose of glucocorticoids might be 
insufficient for patients with poor glucocorticoid sensitivity, which may influence the 
risk of the onset of CLAD after LT.  
Recently, a screening analysis of more than 530000 SNPs revealed that the 
functional single nucleotide polymorphism (SNP) rs37972, which maps to the 
glucocorticoid-induced transcript 1 gene (GLCCI1) and modulates glucocorticoid 
sensitivity, is associated with a decreased efficiency of glucocorticoid inhalation 
therapy in patients with asthma and chronic obstructive pulmonary disease (COPD) 
[14, 15]. Because the GLCCI1 gene is strongly expressed in the lung and lymphoid 
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tissues, including T and B lymphocytes, the pharmacologic response to 
glucocorticoids and the postoperative lung graft function in recipients of LT might also 
be influenced by the presence of this functional GLCCI1 variant, similar to the patients 
with asthma and COPD described above [14, 15]. However, the association between 
the presence of the functional GLCCI1 variant and the postoperative lung graft function 
in recipients of LT remains to be clarified.  
In this study, we investigated the association between the functional GLCCI1 
gene polymorphism modulating glucocorticoid sensitivity and the postoperative lung 
graft function, including the risk of development of CLAD after LT.  
  





This was a single-center retrospective cohort study conducted in a cohort of 71 
patients who underwent LT, including 33 cases of cadaveric LT (CLT) and 38 cases of 
living-donor lobar lung transplantation (LDLLT), at Okayama University Hospital 
between October 1998 and June 2014. Blood samples were collected from all 71 
patients between September 2016 and August 2017. The maximum total number of 
human leukocyte antigen (HLA) mismatches could equal 12 in bilateral LDLLT 
involving 2 different donors and 6 in single LDLLT and CLT involving only 1 donor.  
The study protocol (No.1610-037) was approved by the institutional review board 
of Okayama University Hospital. Written informed consent for the study was obtained 
from each of the patients. All of the methods were performed in accordance with the 
relevant guidelines and regulations. 
 
SNP genotyping  
A genotype analysis for the functional polymorphism of the GLCCI1 gene (rs37972) 
was conducted in all 71 patients. Genomic DNA was isolated from whole blood with a 
TaqMan® Sample-to-SNP™ kit (Applied Biosystems, Foster City, CA, USA). Samples 
were analyzed by a TaqMan genotyping assay using the StepOne™ real-time 
polymerase chain reaction (PCR) system (Applied Biosystems) in a 96-well array plate 
that included 4 blank wells as negative controls. The polymerase chain reaction (PCR) 
profile consisted of an initial denaturation step at 95 °C for 20 secs, 40 cycles at 95 °C 
for 3 secs, and at 60 °C for 20 secs. The PCR products were analyzed by the 
StepOne™ Software Ver 2.3 (Applied Biosystems). To assess the quality of the 
genotyping, repeat genotyping was conducted in a randomly selected 5% of the 
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samples, and 100% agreement was confirmed. Based on the results of the genotyping, 
the patients were divided into three groups: the homozygous mutant T allele (TT) 
group, the heterogeneous mutant allele (CT) group, and the homozygous wild-type 
allele (CC) group. 
 
The evaluation of the pulmonary function 
To evaluate the postoperative changes in the pulmonary function parameters over time, 
the forced expiratory volume in 1 second (FEV1; an indicator for diagnosing 
obstructive CLAD [bronchiolitis obliterans syndrome, BOS]) [16], forced vital capacity 
(FVC; an indicator to diagnose restrictive CLAD [restrictive allograft syndrome, RAS]) 
[16], and total lung capacity (TLC; the indicator originally used to diagnose RAS) [17], 
were measured at 3, 6,12, 24, and 36 months after LT and compared with the 
postoperative stable baseline values among the 3 groups. The postoperative stable 
baseline values were calculated as the mean values between the two best points in 
postoperative pulmonary function tests. In addition, a subgroup analysis was 
performed based on the type of lung donor (cadaveric or living). CLAD was diagnosed 
using the classification system proposed by the International Society for Heart and 
Lung Transplantation (ISHLT) [16]. For the differential diagnosis of CLAD, a blood 
examination, chest X-ray, computed tomography of the chest, ventilation-perfusion 
scanning, the 6-minute walk test, electrocardiogram, and echocardiogram were also 
performed at the same time as the pulmonary function testing. 
 
Statistical analyses 
All statistical analyses were performed using the GraphPad Prism 7.04 software 
program (San Diego, CA, USA). The postoperative changes in the pulmonary function 
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parameters were expressed as the mean percentages ± standard errors of the 
baseline values. Difference in the baseline characteristics among the groups were 
tested by the Kruskal-Wallis test for continuous variables and Pearson’s chi-square 
test for categorical variables. Differences among the % baseline values of the 
individual measures in the different genotype groups were analyzed by a one-way 
analysis of variance followed by Tukey’s test for individual between-group 
comparisons. The CLAD-free survival rate was analyzed using the Kaplan–Meier 
method, and the log rank test was used for the statistical comparison of the differences 
among the groups. Differences were considered significant at P <0.05.  
  




The patient characteristics are shown in Table 1. The frequencies of the GLCCI1 gene 
polymorphism in our cohort were similar to those reported in a previous study [18]. 
The clinical characteristics of the patients were similar among the three groups. There 
were no significant differences in the previously described risk factors for CLAD, 
including HLA mismatches, cytomegalovirus mismatches, primary graft dysfunction, 
acute rejection, and gastroesophageal reflux disease [19]. The total amount of 
glucocorticoids administered during the first 90 days after LT and the maintenance 
dose of glucocorticoids did not differ significantly among the three groups. CLAD 
developed in nine patients during the first three years after LT. 
As shown in Fig. 1, the percent baseline value of the TLC at 3 years after LT was 
significantly lower in the TT group than in the CC group (P = 0.029) (Fig. 1a). In 
contrast, there were no significant differences in the percent baseline values of the 
FEV1 or FVC at three years after LT among the three genotype groups (Fig. 1b, c). Of 
note, in the recipients of CLT (Table 2), the percent baseline value of TLC as well as 
that of FEV1 at 3 years after LT was significantly lower in the TT group than in the CC 
group (TLC, P = 0.031; FEV1, P = 0.0074) (Fig. 2a, b).  
The CLAD-free survival rates at three years after LT were similar among the three 
groups (Fig. 3a). However, in the recipients of CLT, the CLAD-free survival rate at 3 
years after LT was significantly worse in the TT group than in the CC group (Fig. 3b, 
P = 0.016), whereas no significant differences in the CLAD-free survival rates at 3 
years after LT were noted among the 3 groups (P = 0.82) in the recipients of LDLLT. 
  




In this study, we found that the presence of the GLCCI1 gene polymorphism rs37972, 
which modulates glucocorticoid sensitivity, was associated with a significant decrease 
in the TLC at three years after LT (both CLT and LDLLT). In the recipients of CLT, the 
functional GLCCI1 variant was associated with a significant decrease in not only the 
TLC but also of the FEV1 and also a significantly worse CLAD-free survival rate at 
three years after CLT. These results suggest that this SNP might be a risk factor for a 
decline in the TLC after LT as well as for a decline in the FEV1 and the development 
of CLAD after CLT.  
Although glucocorticoid sensitivity in LT recipients has received little attention to 
date, the recipients with the TT genotype of GLCCI1 showed a lower TLC at three 
years after LT than other genotypes in this study. This result indicates that, for patients 
with a decreased glucocorticoid sensitivity, the routinely used maintenance dose of 
glucocorticoid might not be sufficient to prevent a decline in the TLC after LT. Individual 
glucocorticoid sensitivities can be influenced by various factors, including genetic 
factors, the number of cellular glucocorticoid receptors, and the availability of 
glucocorticoids [6-11]. The GLCCI1 genotype may influence dexamethasone-induced 
apoptosis of immune cells [14, 20]. In addition, different foci of lymphoid neogenesis 
in different anatomical compartments of the lung, such as small airways and many 
anatomical compartments of the lung, may contribute to different phenotypes of CLAD 
(e.g. BOS and RAS) [21]. We therefore speculated that, in LT recipients with 
decreased glucocorticoid sensitivity, the decreased induction of apoptosis of 
lymphocytes might trigger lymphoid neogenesis, predominantly in the anatomical 
compartments of the lung, causing a decline in the TLC after LT. In addition, our study 
focused on the GLCCI1 variant in the recipients and not the donors. This is because 
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lymphoid neogenesis in the transplanted lung has been shown to be derived from the 
recipient’s bone marrow [22], which is closely involved in the development of allograft 
rejection after LT. Further examinations will be required to clarify the mechanism 
underlying the decline in the TLC in LT recipients with decreased glucocorticoid 
sensitivity. 
Regarding the pulmonary function markers of CLAD, the GLCCI1 variant was 
associated with a significant difference only in the TLC, but not in the FEV1 or FVC 
after LT, although in the subgroup analysis, there was a significant difference in the 
TLC and FEV1 in the TT group compared with the CC group in the recipients of CLT. 
Originally, RAS was characterized by upper lobe-predominant fibrotic changes and a 
restrictive pulmonary function test profile, defined as FEV1 ≤80% of the baseline FEV1, 
and TLC ≤90% of the baseline TLC for ≥3 weeks [17]. FVC has since been proposed 
as a more practically measured marker for diagnosing RAS [16], as TLC is not 
routinely measured at LT centers worldwide. However, our results suggest that TLC 
might be a more sensitive indicator for diagnosing RAS than FVC, as previously 
described [17].  
The differences in the outcomes between CLT and LDLLT could reflect the 
postoperative expansion of the undersized lobar grafts after LDLLT. LDLLT is still a 
realistic option for resolving the severe donor shortage in Japan, and in LDLLT, the 
right and left lower lobes from two healthy donors are implanted in the recipient in 
place of the whole lungs. Because of the placement of undersized lobar grafts into the 
large chest cavity of the recipient, the FEV1 and FVC can increase up to two years 
after LDLLT [23]. Therefore, the expansion of the transplanted lobes during the first 
two years after LDLLT can be offset by a reduction in the TLC. Furthermore, because 
of the immunogenic heterogeneity of the transplanted lobes obtained from two 
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different donors, CLAD develops unilaterally in most recipients after LDLLT, and the 
unaffected contralateral lobar lung acts as a reservoir [24]. These characteristics might 
enable the maintenance of the pulmonary function after LDLLT and lend support to 
our finding of the GLCCI1 variant being associated with a worse CLAD-free survival 
only after CLT. A better understanding of the effect of the GLCCI1 variant in LDLLT 
recipients might be obtained from the long-term follow-up of these patients. 
Several limitations associated with the present study warrant mention. First, this 
was a retrospective study conducted at a single transplant center, and the number of 
patients was small. Second, the follow-up period was middling, and longer follow-up 
periods will be required for the further validation of the incidence of CLAD. Third, this 
study targeted only Japanese patients, thereby limiting the generalizability of the 
results. 
In conclusion, the presence of a functional GLCCI1 gene polymorphism 
modulating glucocorticoid sensitivity was associated with a decline in the TLC at three 
years after LT. Furthermore, in the recipients of CLT in particular, the GLCCI1 variant 
was associated with a decrease in the TLC and FEV1 and a worse CLAD-free survival 
at three years after CLT. Genotyping for this SNP might prove useful for adjusting the 
glucocorticoid dose to prevent a decline in the TLC after LT and reducing the risk of 
CLAD after CLT. 
  




Funding: This work was supported by a grant-in-aid for Scientific Research grant no. 
15K10256 from the Japan Society for the Promotion of Science. 
 
Compliance with ethical standards 
Conflict of Interest: Haruchika Yamamoto and his co-authors have no conflicts of 
interest. 




[1] Bloom RD, Goldberg LR, Wang AY, Faust TW, Kotloff RM. An overview of solid 
organ transplantation. Clin Chest Med. 2005; 26:529-43.  
[2] Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival 
improvement in the United States: the long-term does not mirror the dramatic 
short-term success. Am J Transplant. 2011; 11:1226-35.  
[3] Chambers DC, Yusen RD, Cherikh WS, Goldfarb SB, Kucheryavaya AY, Khusch 
K, et al. The Registry of the International Society for Heart and Lung 
Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-
2017; Focus Theme: Allograft ischemic time. J Heart Lung Transplant. 2017; 
36:1047-59. 
[4] Korom S, Boehler A, Weder W. Immunosuppressive therapy in lung 
transplantation: state of the art. Eur J Cardiothorac Surg. 2009; 35:1045-55. 
[5] Scheffert JL, Raza K. Immunosuppression in lung transplantation. J Thorac Dis. 
2014; 6:1039-53.  
[6] Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 
2009; 373:1905-17.  
[7] Hodge G, Hodge S, Holmes-Liew CL, Reynolds PN, Holmes M. Loss of 
glucocorticoid receptor from pro-inflammatory T cells after lung transplant. J Heart 
Lung Transplant. 2014; 33:957-62. 
[8] Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF. Clinical 
features associated with glucocorticoid receptor polymorphisms. An overview. Ann 
N Y Acad Sci. 2009; 1179:179-98.  
[9] Quax RA, Manenschijn L, Koper JW, Hazes JM, Lamberts SW, van Rossum EF, 
et al. Glucocorticoid sensitivity in health and disease. Nat Rev Endocrinol. 2013; 




[10] Ramamoorthy S, Cidlowski JA. Exploring the molecular mechanisms of 
glucocorticoid receptor action from sensitivity to resistance. Endocr Dev. 2013; 
24:41-56.  
[11] Rosewicz S, McDonald AR, Maddux BA, Goldfine ID, Miesfeld RL, Logsdon CD. 
Mechanism of glucocorticoid receptor down-regulation by glucocorticoids. J Biol 
Chem. 1988; 263:2581-4. 
[12] Borro JM, Sole A, De la Torre M, Pastor A, Tarazona V. Steroid withdrawal in lung 
transplant recipients. Transplant Proc. 2005; 37:3991-3. 
[13] Shitrit D, Bendayan D, Sulkes J, Bar-Gil Shitrit A, Huerta M, Kramer MR. 
Successful steroid withdrawal in lung transplant recipients: result of a pilot study. 
Respir Med. 2005; 99:596-601.  
[14] Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, et al. 
Genomewide association between GLCCI1 and response to glucocorticoid 
therapy in asthma. N Engl J Med. 2011; 365:1173-83.  
[15] van den Berge M, Hiemstra PS, Postma DS. Genetics of glucocorticoids in asthma. 
N Engl J Med. 2011; 365:2434-5; author reply 5-6.  
[16] Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification 
system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014; 
33:127-33.  
[17] Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, et al. 
Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft 
dysfunction. J Heart Lung Transplant. 2011; 30:735-42.  
[18] The International HapMap Project. Nature. 2003; 426:789-96.  
[19] Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, et al. Bronchiolitis 
Yamamoto et al. 
 
 15 
obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung 
Transplant. 2002; 21:297-310.  
[20] Chapman MS, Askew DJ, Kuscuoglu U, Miesfeld RL. Transcriptional control of 
steroid-regulated apoptosis in murine thymoma cells. Mol Endocrinol. 1996; 
10:967-78.  
[21] Sato M, Hirayama S, Matsuda Y, Wagnetz D, Hwang DM, Guan Z, et al. Stromal 
activation and formation of lymphoid-like stroma in chronic lung allograft 
dysfunction. Transplantation. 2011; 91:1398-405.  
[22] Kreisel D, Sugimoto S, Zhu J, Nava R, Li W, Okazaki M, et al. Emergency 
granulopoiesis promotes neutrophil-dendritic cell encounters that prevent mouse 
lung allograft acceptance. Blood. 2011; 118:6172-82.  
[23] Yamane M, Date H, Okazaki M, Toyooka S, Aoe M, Sano Y. Long-term 
improvement in pulmonary function after living donor lobar lung transplantation. J 
Heart Lung Transplant. 2007; 26:687-92.  
[24] Miyamoto E, Chen F, Aoyama A, Sato M, Yamada T, Date H. Unilateral chronic 
lung allograft dysfunction is a characteristic of bilateral living-donor lobar lung 
transplantation. Eur J Cardiothorac Surg. 2015; 48:463-9. 




Fig. 1. Postoperative changes in the pulmonary function at three years after lung 
transplantation (LT) in the recipients according to the GLCCI1 genotype. (a) Total 
lung capacity (TLC), (b) forced expiratory volume in 1 second (FEV1), (c) forced vital 
capacity (FVC) in all the recipients of LT. The percent baseline values of TLC in all of 
the recipients of LT (a) in the homozygous mutant T allele (TT) group were significantly 
lower than those in the homozygous wild-type allele (CC) group.  
 
Fig. 2. Postoperative changes in the pulmonary function at 3 years after 
cadaveric lung transplantation (CLT) in the recipients according to the GLCCI1 
genotype. (a) Total lung capacity (TLC), (b) forced expiratory volume in 1 second 
(FEV1), (c) forced vital capacity (FVC) in the recipients of CLT. The percent baseline 
values of TLC (a) and FEV1 (b) in the recipients of CLT in the homozygous mutant T 
allele (TT) group were significantly lower than those in the homozygous wild-type allele 
(CC) group. 
 
Fig. 3. The chronic lung allograft dysfunction (CLAD)-free survival after lung 
transplantation (LT) according to the rs37972 genotype. (a) There were no 
significant differences in the CLAD-free survival among the three groups after LT. (b) 
In the recipients of cadaveric lung transplantation (CLT), the CLAD-free survival in the 
homozygous mutant T allele (TT) group was significantly worse than that in the 
homozygous wild-type allele (CC) group (P = 0.016). 
